Ernexa Therapeutics (ERNAW) Total Current Liabilities (2010 - 2026)

Ernexa Therapeutics has reported Total Current Liabilities for 17 years, with the latest figure at $3.5 million in Q1 2026.

• For the quarter ending Q1 2026, Total Current Liabilities fell 66.88% year-over-year to $3.5 million; the trailing twelve-month figure through Mar 2026 stood at $3.5 million (down 66.88% YoY), and the FY2025 full-year result was $3.1 million, up 5.96% from the prior year.
• Total Current Liabilities for Q1 2026 stood at $3.5 million, up from $3.1 million in the prior quarter.
• The five-year high for Total Current Liabilities was $10.4 million in Q1 2025, with the low at $2.1 million in Q3 2025.
• Historically, Total Current Liabilities has averaged $6.3 million across 5 years, with a median of $7.1 million in 2022.
• Annual changes were most pronounced in 2022 — Total Current Liabilities surged 108.16% — and 2025, when it plunged 78.46%.
• Ernexa Therapeutics' Total Current Liabilities stood at $7.7 million in 2022, then fell by 14.12% to $6.6 million in 2023, then sank by 55.3% to $2.9 million in 2024, then advanced by 5.96% to $3.1 million in 2025, then advanced by 11.05% to $3.5 million in 2026.
• The last three Total Current Liabilities figures came in at $3.5 million (Q1 2026), $3.1 million (Q4 2025), and $2.1 million (Q3 2025), per Business Quant data.